Baseline cardiac magnetic resonance imaging versus baseline endomyocardial biopsy for the prediction of left ventricular reverse remodeling and prognosis in response to therapy in patients with idiopathic dilated cardiomyopathy

Takeru Nabeta · Takayuki Inomata · Yuichiro Iida · Yuki Ikeda · Miwa Iwamoto · Shunsuke Ishii · Takanori Sato · Ichiro Watanabe · Takashi Naruke · Hisahito Shinagawa · Toshimi Koitabashi · Ichiro Takeuchi · Mototsugu Nishii · Yusuke Inoue · Tohru Izumi

Heart Vessels (2014) 29:784–792
DOI 10.1007/s00380-013-0415-1

Abstract Endomyocardial biopsy (EMB) and late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) imaging performed at baseline are both used to evaluate the extent of myocardial fibrosis. However, no study has directly compared the effectiveness of these diagnostic tools in the prediction of left ventricular reverse remodeling (LVRR) and prognosis in response to therapy in patients with idiopathic dilated cardiomyopathy (IDCM). Seventy-five patients with newly diagnosed IDCM who were undergoing optimal therapy were assessed at baseline using LGE-CMR imaging and EMB; the former measured LGE area and the latter measured collagen volume fraction (CVF) as possible predictive indices of LVRR and cardiac event-free survival. Among all the baseline primary candidate factors with \( P < 0.2 \) as per univariate analysis, multivariate analysis indicated that only LGE area was an independent predictor of subsequent LVRR (\( \beta = 0.44; 95 \% \) confidence interval (CI) 0.87–2.53; \( P < 0.001 \)), as indicated by decreasing left ventricular end-systolic volume index over the 1-year follow-up. Kaplan–Meier curves indicated significantly lower cardiac event-free survival rates in patients with LGE at baseline than in patients without (\( P < 0.01 \)). By contrast, there was no significant difference in prognosis between patients with CVF values above (severe fibrosis) and below (mild fibrosis) the median of 4.9 %. Cox proportional hazard analysis showed that LGE area was an independent predictor of subsequent cardiac events (hazard ratio 1.06; 95 % CI 1.02–1.10; \( P < 0.01 \)). The degree of myocardial fibrosis estimated by baseline LGE-CMR imaging, but not that estimated by baseline EMB, can predict LVRR and cardiac event-free survival in response to therapy in patients with newly diagnosed IDCM.

Keywords Fibrosis · Magnetic resonance imaging · Biopsy · Dilated cardiomyopathy

Introduction

Left ventricular (LV) remodeling is a major pathogenic mechanism in the progression of idiopathic dilated cardiomyopathy (IDCM) and is a confirmed predictor of future cardiac events, including severe heart failure (HF) [1]. In some IDCM patients, particularly those receiving \( \beta \)-blockers [2] or cardiac resynchronization therapy (CRT) [3], the left ventricle undergoes volume reduction and normalization of shape with a concomitant improvement in pump function, a positive therapeutic response known as LV reverse remodeling (LVRR) [4]. The incidence and degree of LVRR were higher in IDCM patients who survived for at least 6 months during drug therapy than in patients who died or required transplantation, indicating that LVRR after therapy is correlated with a better prognosis [5, 6].

Myocardial fibrosis is a common feature of LV remodeling, and the increased ventricular stiffness associated with excess collagen accumulation can increase the risk of HF in patients with chronic cardiovascular diseases such as...
hypertension [7, 8]. Histologic evaluation by endomyocardial biopsy (EMB) was once the standard tool for the quantification of myocardial fibrosis [8], but EMB is now being supplanted by late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) imaging as the diagnostic standard [9]. However, there have been no reports comparing the effectiveness of baseline EMB with that of baseline LGE-CMR imaging in estimating myocardial fibrosis for the prediction of LVRR and prognosis in response to therapy. To the best of our knowledge, this is the first report to directly compare the prognostic significance of EMB-derived collagen volume fraction (CVF) with LGE-CMR imaging-derived LGE area in patients with newly diagnosed IDCM undergoing therapy.

Patients and methods

Subjects

A total of 91 patients with newly diagnosed IDCM and an LV ejection fraction (LVEF) of <45% on baseline echocardiography were referred to the Kitasato University Hospital between January 2007 and June 2012. Both LGE-CMR imaging and EMB were performed in these patients to determine the etiology of cardiomyopathy and the extent of fibrosis prior to treatment. Exclusion criteria were the presence of significant coronary artery disease (defined as the presence of >50% luminal stenosis on coronary angiography or prior myocardial infarction), myocarditis, severe valvular heart disease, and/or chronic renal failure (estimated glomerular filtration rate <30 ml/min). Patients whose CMR images were of poor quality were also excluded. Six patients who underwent mitral valvoplasty and/or left ventriculectomy during the follow-up period were excluded from final analyses. Ten patients who were unable to be followed for >6 months were also excluded. A total of 75 patients were finally selected as the study subjects. Therapies for HF were in accordance with current guidelines [10] and were administered by experienced cardiologists. The study protocol was approved by our institution’s committee on human investigation, and written informed consent was obtained from all patients prior to study initiation.

Clinical measurement and morphometric evaluation

Relevant clinical parameters derived from general laboratory analyses, electrocardiography, and echocardiography were recorded at baseline and approximately 1 year later (326 ± 102 days). Baseline data were collected with patients in a clinically stable condition. Transthoracic echocardiography was performed using an APLIO SSA-770A system (Toshiba, Tochigi, Japan), and repeated by the same experienced ultrasonographers whenever possible. M-mode images were obtained in the left parasternal long-axis view to measure the dimension of each chamber. LVEF and LV end-systolic volume index (LVESVI) were calculated by the modified Simpson method using biplanar images from apical views.

LGE-CMR imaging

All LGE-CMR examinations were performed at baseline using a 1.5-T clinical scanner (Signa HDxt 1.5T; GE Healthcare, Milwaukee, WI, USA) with a maximum gradient strength of 33 mT/m and a slew rate of 120 mT/m/s. An eight-channel phased-array coil and vector electrocardiograph (ECG) were used for signal reception and cardiac gating, respectively. ECG-gated two-dimensional LGE images were acquired 10–15 min after the intravenous injection of 0.2 mmol/kg gadolinium using segmented inversion recovery fast gradient-echo sequences with the following parameters: echo time, 4.2 ms; repetition time, 8.0 ms; views per segment, 24; flip angle, 20°; inversion time, 150–220 ms; bandwidth, ±25 kHz; number of excitations, 1; in-plane resolution, 1.5 × 1.7 mm²; field of view, 340 mm × 340 mm; slice thickness, 8 mm; interslice gap, 8 mm; and four slices acquired in the LV short axis over two R–R intervals. The presence of LGE was determined by two experienced and independent observers blinded to patient outcome. The extent of LGE was expressed as “LGE area,” defined as an area showing a signal intensity of ≥5 standard deviations (SDs) above the mean of the remote reference myocardium. LGE area was quantified by semiautomatic planimetry on the short-axis contrast images using Ziostation 2 (Ziosoft, Tokyo, Japan).

EMB

At least three EMB specimens were obtained at baseline from the posterior wall of the LV chamber. The interval between LGE-CMR imaging and EMB was <3 weeks. When required, tissue sections were stained with Masson’s trichrome to distinguish cardiomyocytes from connective tissue, and labeled with antibodies against CD3, CD68, and tenascin C to exclude infiltrative myocarditis [11]. Serial images of the tissue sections were analyzed using a projection microscope (Lumina Vision 3.3.2.0; Mitani, Fukui, Japan) to estimate the degree of myocardial fibrosis. CVF was calculated by averaging the total connective tissue area in 10 representative fields on sections containing no endocardium or blood vessels [12]. Histologic evaluation was performed by two well-trained pathologists blinded to patient identity or condition.
Clinical observation and statistical analysis

Patients were divided into groups by the presence or absence of LGE on baseline LGE-CMR images (LGE+ and LGE− groups) and by the median value of CVF derived from baseline EMB (≤median CVF or mild fibrosis group, and ≥median CVF or severe fibrosis group). Continuous variables expressed as mean ± SD were compared between groups using Student’s t tests, whereas binary variables were compared using the Chi-square test with Yates’ correction for continuity when necessary. Correlation between LGE area and CVF were examined using Spearman’s rank-correlation test.

The change in LVESVI at 1 year after treatment as revealed by echocardiography was set as a primary end point of this study, considering the contributing factors for LVRR. To predict the extent of LVRR from baseline variables, univariate screening of all baseline clinical and laboratory variables was performed. Then a stepwise backward conditional algorithm was subsequently applied to selected candidates with $P < 0.2$ as per univariate analysis to estimate the multivariable regression equation. Event-free survival curves were drawn according to the Kaplan–Meier method and compared using the log-rank test. Cardiovascular events, including sudden death, readmission for HF exacerbation, and major ventricular arrhythmias were considered as secondary end points. For the univariate analysis, we included potential covariates that affect HF prognosis, as per earlier reports [4, 13–18]. To test for independent predictors of cardiac events, clinical variables with $P ≤ 0.04$ as per univariate analysis were examined using multivariate analysis in a Cox proportional hazard model. All statistical analyses were performed using JMP Pro 9.0.2 (SAS Institute, Cary, NC, USA). All $P$ values were two-sided, and $P < 0.05$ was considered statistically significant.

Results

Baseline characteristics in relation to LGE measured using LGE-CMR imaging and CVF measured using EMB

In total, 75 patients (mean age 56 ± 13 years; 65 % male) admitted for treatment of IDCM met the inclusion criteria for this study. At baseline, LVEF was 30 ± 7 % while HF was sufficiently compensated in most cases, with 85 % of

| Table 1 Baseline characteristics | Total (n = 75) | LGE+ (n = 36) | LGE− (n = 39) | $P$ value |
|---------------------------------|--------------|--------------|--------------|-----------|
| Age (years)                     | 56 ± 13      | 59 ± 14      | 54 ± 12      | 0.091     |
| Sex, males, n (%)               | 49 (65)      | 24 (66)      | 25 (64)      | 0.816     |
| NYHA (I:II:III:IV)              | 13:51:11:0   | 6:24:6:0     | 7:27:5:0     | 0.894     |
| SBP (mmHg)                      | 112 ± 16     | 108 ± 17     | 116 ± 14     | 0.026*    |
| Heart rate (beats/min)          | 77 ± 13      | 75 ± 12      | 79 ± 13      | 0.143     |
| Electrocardiographic data       |              |              |              |           |
| QRS duration (ms)               | 115 ± 26     | 113 ± 22     | 118 ± 29     | 0.388     |
| Left bundle branch block, n (%) | 10 (13)      | 1 (3)        | 9 (23)       | 0.015*    |
| Echocardiogram data             |              |              |              |           |
| LVEF (%)                        | 30.2 ± 7.3   | 31.4 ± 7.4   | 29.1 ± 7.1   | 0.163     |
| LVESVI (ml/m²)                  | 119 ± 36     | 126 ± 37     | 113 ± 35     | 0.106     |
| Laboratory data                 |              |              |              |           |
| BNP (pg/ml)                     | 240 ± 196    | 236 ± 180    | 244 ± 212    | 0.903     |
| BUN (mg/dl)                     | 18.6 ± 6.16  | 19.4 ± 5.5   | 17.9 ± 6.67  | 0.288     |
| Creatinine (mg/dl)              | 0.88 ± 0.25  | 0.85 ± 0.23  | 0.90 ± 0.28  | 0.373     |
| Total bilirubin (mg/dl)         | 0.69 ± 0.30  | 0.73 ± 0.26  | 0.66 ± 0.34  | 0.326     |
| Treatment, n (%)                |              |              |              |           |
| β-Blocker                       | 71 (95)      | 33 (92)      | 38 (97)      | 0.345     |
| Carvedilol equivalent dose (mg/day) | 12 ± 7.6 | 10 ± 7.9    | 15 ± 7.0    | 0.019*    |
| ACEI/ARB                        | 74 (99)      | 36 (100)     | 38 (97)      | 1         |
| MRB                             | 46 (61)      | 26 (72)      | 20 (51)      | 0.096     |
| ICD                             | 6 (8)        | 4 (11)       | 2 (5)        | 0.337     |
| CRT                             | 5 (7)        | 3 (8)        | 2 (5)        | 0.578     |
| CVF on EMB (%)                  | 7.05 ± 6.24  | 6.52 ± 5.98  | 7.61 ± 6.54  | 0.432     |

* $P < 0.05$
patients exhibiting New York Heart Association (NYHA) functional class ≤ III under standard therapies. Thirty-six patients (48 %) exhibited positive LGE on LGE-CMR images, with a mean LGE area of 6.4 ± 9.9 %. There were no significant differences in clinical parameters between the LGE+ and LGE− groups, including CVF as determined by EMB, plasma B-type natriuretic peptide (BNP) and serum creatinine levels, QRS width, and LVESVI, with the exception of systolic blood pressure, which was higher in the LGE+ group (116 ± 14 mmHg) than in the LGE− group (108 ± 17 mmHg; \(P = 0.026\); Table 1). Surprisingly, LGE area was not correlated with CVF (Fig. 1). Almost all patients were prescribed β-blockers together with angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers, while approximately half were also prescribed aldosterone blockers despite significant differences in carvedilol equivalent dose (10.0 ± 7.9 vs 15.0 ± 7.0 mg/day; \(P = 0.019\)). In addition, there were no significant differences in the proportion of patients with implantable defibrillation or CRT devices between the LGE+ and LGE− groups (Table 1).

Baseline LGE and CVF as predictors of LVRR and prognosis

Morphometric and functional deterioration of the left ventricle was evaluated by echocardiography. Baseline characteristics were similar between groups defined by the presence of LGE and by the CVF value. However, LVRR at approximately 1 year after the initiation of optimal therapy was more advanced in the LGE− group than in the LGE+ group (Fig. 2). Univariate analysis showed that the significant predictors of subsequent LVRR among the different clinical parameters at baseline included LGE area, but not CVF. Of all the primary candidate factors with \(P < 0.2\) as per univariate analysis, multivariate analysis indicated that only LGE area (\(\beta = 0.44; 95 \% \text{ confidence interval (CI) } 0.87 - 2.53; P < 0.001\)) and plasma BNP levels were independent predictors of subsequent LVRR (Table 2).

The cardiac events were observed in 13 patients (11 LGE+ and 2 LGE− cases): 11 with HF hospitalization and 2 with major ventricular arrhythmias. Kaplan–Meier curves indicated significantly higher cardiac event-free survival rates in the LGE− group than in the LGE+ group (\(P < 0.01\)), but there was no significant difference in prognosis between the group with a CVF value above the median (4.9 %) and the group with a CVF value below the median (Fig. 3). Univariate Cox proportional hazard analysis showed that the significant predictors of subsequent cardiac events (\(P \leq 0.04\)) among the different clinical parameters at baseline included LGE area and systolic blood pressure. Multivariate analysis indicated that out of these primary candidates, only LGE area was
Table 2 Univariate and multivariate analyses for the change of LVESVI

|                      | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | \( \beta \) coefficient | 95 % CI     | \( P \) value | \( \beta \) coefficient | 95 % CI     | \( P \) value |
| Age                  | -0.02               | -0.74 to 0.62         | 0.862        | -0.24               | -0.09 to -0.01 | 0.028*        |
| SBP                  | -0.057              | -0.71 to 0.43         | 0.625        | -0.091              | -1.64 to 0.72 | 0.436         |
| Heart rate           | -0.067              | -0.92 to 0.51         | 0.567        | 0.038               | -1.19 to 1.65 | 0.333         |
| QRS duration         | -0.032              | -0.40 to 0.31         | 0.787        | -0.153              | -0.07 to 0.02 | 0.189         |
| Left bundle branch block | -0.098           | -18.7 to 7.60         | 0.404        | -0.089              | -2.02 to 0.90 | 0.447         |
| BNP                  | -0.024              | -39.2 to 31.8         | 0.836        | -0.034              | -18.7 to 7.60 | 0.404         |
| Creatinine           |                     |                      |              | -0.034              | -18.7 to 7.60 | 0.404         |
| Total bilirubin      |                     |                      |              | -0.091              | -1.64 to 0.72 | 0.436         |
| \( \beta \)-Blocker dose | -0.015           | -0.40 to 0.31         | 0.404        | 0.038               | -1.19 to 1.65 | 0.333         |
| CVF on EMB           | 0.038               | -0.74 to 2.35         | <0.001**     | 0.388               | 0.67 to 2.35  | <0.001**      |
| LGE area             |                     |                      |              |                     |               |               |

\( \beta \)-Blocker dose expressed as equivalent to carvedilol

*SBP* systolic blood pressure, *BNP* brain natriuretic peptide, *BUN* blood urea nitrogen, *CVF on EMB* collagen volume fraction on endomyocardial biopsy, *LGE* late gadolinium enhancement cardiovascular magnetic resonance

*\( P < 0.05\), **\( P < 0.01\)

Fig. 3 Event-free survival in groups stratified by late gadolinium enhancement (*LGE*) determined by LGE cardiac magnetic resonance imaging, and collagen volume fraction (*CVF*) determined by endomyocardial biopsy. Kaplan–Meier analysis illustrates poorer long-term outcome in patients with LGE positivity (LGE+) than in patients with LGE negativity (LGE-) at baseline (a). By contrast, no difference in long-term outcome was found between the group with CVF below the median value (mild fibrosis) and the group with CVF above the median value (severe fibrosis) (b).

Discussion

Mechanism and clinical relevance of LGE-CMR

CMR imaging is now established as the reference imaging method to assess cardiac anatomy and function together with myocardial characterization [19]. In particular, LGE-CMR imaging can detect the presence and extent of myocardial fibrosis [9]. An earlier study that involved the examination of myocardial tissue samples obtained from autopsy or heart transplantation revealed segmental and replacement fibrosis corresponding to LGE-CMR findings [20]. The presence of LGE has also been associated with a marked increase in LV volume and severely impaired systolic function [21]. Furthermore, several reports have demonstrated that LGE-CMR imaging is a predictor of adverse outcome in patients with IDCM [22, 23], as shown in this study. The overall occurrence of LGE (48%) at baseline in this patient cohort with confirmed IDCM was similar to that found in previous studies [22, 23] (Table 1), indicating that the methodology was sufficiently sensitive to detect fibrosis associated with IDCM.

Clinical parameters predictive of LVRR

The presence and extent of LVRR is of potential prognostic value for the stratification of long-term risk in patients with impaired LV contraction [24]. Although the precise mechanisms of LVRR have not been elucidated, several hypothetical mechanisms have been proposed on the basis of the efficacy of specific clinical interventions. These
include hemodynamic improvement, direct action by cardiomyocytes, and electrical/mechanical resynchroniza-
tion [25]. A few previous studies have attempted to identify the early clinical characteristics of IDCM that are predic-
tive of LVRR and useful for long-term prognosis in response to tailored medical therapy. Merlo et al. [26] found that higher baseline systolic blood pressure and the absence of left bundle branch block were predictors of LVRR in a large population of IDCM patients. Kawai et al. [27] found that higher systolic blood pressure and lower pulmonary arterial wedge pressure at diagnosis were independent predictors of LVRR. The present study, however, did not show an association between any hemody-
namic parameters and the presence or extent of LVRR, presumably because this study included a distinct clinical group composed exclusively of newly developed IDCM patients in a clinically stable condition.

Several cardiac imaging modalities have been developed to predict subsequent LVRR. Several studies have suggested that iodine-123 metaiodobenzylguanidine (MIBG) myocardial scintigraphy is a particularly powerful tool, not only for detecting myocardial abnormalities in the adre-
nergic nervous system of IDCM patients [28] but also for predicting the response to β-blocker therapy [29]. How-
ever, MIBG scintigraphy has not yet achieved broad clinical acceptance for these purposes because the quantitative parameters differ between institutions and the tracer is not widely available [30]. On the other hand, CMR provides highly accurate and reproducible measures of pathologic tissue changes, including myocardial fibrosis. The degree of myocardial fibrosis detected by baseline LGE-CMR imaging in this study was an independent predictor of LVRR in response to optimal medical therapy (Table 2; Fig. 2), consistent with the findings of previous reports [31].

Baseline LGE-CMR imaging versus EMB as indicators for myocardial fibrosis

Myocardial fibrosis is associated with both ventricular remodeling leading to HF and a scar-related re-entrant mechanism linked to ventricular arrhythmia. Although it has been established that both LGE and CVF as measured by LGE-CMR imaging and EMB can estimate the extent of fibrosis in myocardial tissue [20], there was no significant correlation between LGE and CVF (Fig. 1) in this study. Mean CVF in the present study was 7.2 %, consistent with that reported in previous studies [32]; on the other hand, approximately half of the patients were LGE-

| β-Blocker dose expressed as equivalent to carvedilol |

SBP systolic blood pressure, BNP brain natriuretic peptide, BUN blood urea nitrogen, LVEF left ventricular ejection fraction, LVESVI left ventricular end-systolic volume index, LGE late gadolinium enhancement-cardiovascular magnetic resonance, CVF on EMB collagen volume fraction on endomyocardial biopsy

* P < 0.04, ** P < 0.01

### Table 3 Cox proportional hazard regression analysis for incidence of cardiac events

| Univariate analysis | Multivariate analysis |
|---------------------|-----------------------|
|                      | Hazard ratio | 95 % CI | P value | Hazard ratio | 95 % CI | P value |
| Age                 | 1.013        | 0.97–1.06 | 0.53     |             |           |        |
| Male                | 0.597        | 0.20–1.86 | 0.361    | 0.986       | 0.94–1.02 | 0.466   |
| SBP                 | 0.958        | 0.92–1.00 | 0.026*   | 0.986       | 0.94–1.02 | 0.466   |
| Heart rate          | 0.979        | 0.94–1.02 | 0.339    |             |           |        |
| Left bundle branch block | 0.006  | 0.99–1.00 | 0.049    |             |           |        |
| BNP                 | 1.002        | 0.99–1.00 | 0.075    |             |           |        |
| LVEF                | 1.072        | 0.99–1.16 | 0.069    |             |           |        |
| LVESVI              | 1.002        | 0.99–1.02 | 0.748    |             |           |        |
| β-Blocker dose      | 0.931        | 0.86–1.00 | 0.055    | 1.06        | 1.01–1.10 | 0.009** |
| CVF on EMB          | 1.055        | 0.98–1.13 | 0.159    |             |           |        |
| LGE area            | 1.068        | 1.03–1.11 | <0.001** |             |           |        |
not exclude increased interstitial fibrosis. Scan sequences for LGE-CMR imaging of diffuse interstitial fibrosis, such as T1 mapping [35] and equilibrium contrast CMR [36], are still in the experimental stages.

Baseline LGE-CMR imaging versus baseline EMB as predictors of LVRR and prognosis

A hallmark of myocardial damage in IDC M patients is myocardial fibrosis. However, the extent of myocardial fibrosis at first presentation and its association with subsequent responses to various therapies have not been examined in requisite detail. The present multivariate analysis clearly demonstrated the prognostic value of LGE area, but not that of CVF, as a predictor of poor LVRR (Table 2) and adverse outcome (Table 3; Fig. 3). The reasons for this result are undetermined. We suggest that LGE-CMR imaging may yield more information about fibrosis over the entire left ventricle in comparison with EMB. The imaging power of LGE-CMR is based on a combination of increased accumulation/distribution of the contrast agent and a prolonged washout period related to the decreased capillary density within myocardial fibrotic tissue [37]. In contrast to the present results, several studies have found a good correlation between CVF and both cardiac events [38] and LVRR [39] in response to β-blockers and other regimens, whereas others have not [26, 40]. However, EMB has several inherent limitations. First, sampling errors restrict the accuracy of biopsy in patients with localized fibrosis, and fibrotic involvement over the entire left ventricle cannot be determined [41]. Furthermore, the predictive value of a local sample depends on the uniformity of myocardial fibrosis, which in turn is related to etiology. CVF may be substantially higher or lower than the average value if fibrosis is highly localized. Although the underlying processes leading to focal fibrosis in IDC M patients are currently unknown, several reports have suggested that focal fibrosis reflects the transition from a compensated (reparative) to a decompensated state associated with a poor prognosis [13].

Clinical implications

The findings of this study have important implications for the clinical management of patients with newly diagnosed IDC M. LGE positivity at baseline may signify the need for more aggressive therapies. The ability to estimate the likelihood of LVRR (or risk of poor LVRR) before initiating therapy should influence treatment strategy. LVEF is a major determinant of feasible therapeutic options, including device implantation, but baseline LVEF may be a poor predictor of subsequent LVRR and prognosis in patients with newly-onset IDC M [26]. When the probability of LVRR is high, even if the baseline LVEF is low, it may be possible to delay dangerous or invasive therapeutic options and wait for subsequent improvement in LV function through pharmacotherapy. For example, although an LVEF of <35 % is a criterion for the use of implantable cardiac defibrillators and/or CRT, these costly and highly invasive treatments may not be necessary for patients with newly diagnosed IDC M and LGE negativity at baseline.

Study limitations

The present study had some limitations. It was a single-center study, so selection bias was a major concern. Because of the low number of cardiac events in our cohort, which comprised a relatively small number of patients, the findings of this observational study should be interpreted with caution. Although LGE-CMR imaging allows for semiquantitative assessment of myocardial structure and function, it is of limited accuracy for the absolute quantification of myocardial fibrosis. Indeed, there is no clear consensus on the optimal intensity threshold to identify fibrosis. Reports have demonstrated the efficacy of LGE patterns such as mid-wall, epicardial, diffuse, and focal enhancement in patients with IDC M [22, 23]. However, the present sample size was insufficient to establish any correlation between different LGE patterns and LVRR in terms of differential risk.

Conclusion

In patients with newly diagnosed IDC M, the degree of myocardial fibrosis detected by LGE-CMR imaging, but not that estimated by EMB, was an independent predictor of LVRR and prognosis in response to optimal medical therapy.

Acknowledgments We thank Dr Keika Hoshi, Kitasato Clinical Research Center, for outstanding assistance with statistical analysis, and Hiroyuki Hata, Department of Radiology, Kitasato University Hospital, for technical assistance with analysis of LGE-CMR imaging. This study was supported in part by a grant-in-aid for scientific research from The Vehicle Racing Commemorative Foundation.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On behalf of an
international forum on cardiac remodeling. J Am Coll Cardiol 35:569–582.
2. Francis GS, Tang WH (2003) Beta-blockers and reverse remodeling: what are the implications? Am Heart J 145:200–202
3. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ, Fisher WG, Ellestad M, Messenger J, Kruger K, Hilpisch KE, Kill MR, Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group (2003) Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 107:1985–1990.
4. Ishii S, Inomata T, Ikeda Y, Nabeta T, Iwamoto M, Watanabe I, Naruke T, Shinagawa H, Koitabashi T, Nishii M, Takeuchi I, Izumi T (2013) Clinical significance of heart rate during acute decompensated heart failure to predict left ventricular reverse remodeling and prognosis in response to therapies in nonischemic dilated cardiomyopathy. Heart Vessels. doi:10.1007/s00380-013-0335-0
5. Hoshikawa E, Matsumura Y, Kudo T, Okawa M, Yasumaki N, Kitaoka H, Furuno T, Takata J, Doi YL (2011) Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β-blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 107:1065–1070.
6. Yu CM, Bleeker GB, Fung JW, Schalij MJ, Zhang Q, van der Wall EE, Chan YS, Kong SL, Bax JJ (2005) Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation 112:1580–1586.
7. Sugihara N, Genda A, Shimizu M, Suematsu T, Kita Y, Minamoto M, Kawagoshi H, Umeda K, Chin S, Takeda R (1998) Diastolic dysfunction and its relation to myocardial fibrosis in essential hypertension. J Cardiol 18:353–361.
8. Díez J (2007) Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens (Greenwich) 9:546–550.
9. Jellis C, Martin J, Narula J, Marwick TH (2010) Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 56:89–97.
10. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michi K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW (2009) 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the international society for heart and lung transplantation. Circulation 119:e391–e479.
11. Tsukada B, Terasaki F, Shimomura H, Otsuka K, Otsuka K, Katahira T, Fujita S, Inamana-yoshida K, Yoshiida T, Hiroe M, Kitaura Y (2009) High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventricularplasty: expression of tenascin C as a possible marker for inflammation. Hum Pathol 40:1015–1022.
12. Fukuji S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shimozaki T, Kagaya Y, Shimokawa H (2008) Long-term inhibition of rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 51:317–326.
13. Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, Lai S, Blumenke DA, Gerstenblith G, Marban E, Tomaselli GF, Lima JA (2008) Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 51:2414–2421.
14. Nishii M, Inomata T, Takehana H, Naruke T, Yanagisawa T, Moriguchi M, Takeda S, Izumi T (2008) Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decenpenated heart failure. J Am Coll Cardiol 51:2329–2335.
15. Cho J, Kim EY, Lee GY, Lee SC, Park SW, Kim DK, Oh JK, Jeon ES (2013) Predictors of left ventricular reverse remodeling and subsequent outcome in nonischemic dilated cardiomyopathy. Circ J 77:462–469.
16. Ohshima K, Hirashiki A, Cheng XW, Hayashi M, Hayashi D, Okumura T, Sakikabira M, Funahashi H, Ohshima S, Murohara T (2011) Impact of mild to moderate renal dysfunction on left ventricular relaxation function and prognosis in ambulatory patients with nonischemic dilated cardiomyopathy. Int Heart J 52:366–371.
17. Chintanaboina J, Haner MS, Sethi A, Patel N, Tanyous W, Lalos A, Pancholy S (2013) Serum bilirubin as a prognostic marker in patients with acute decompensated heart failure. Korean J Intern Med 28:300–305.
18. Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M, Campana C, Perini G, Deorsola A, Masotti G, Tavazzi L, Maggioni AP, Italian Network on Congestive Heart Failure Investigators (2002) Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian Network on Congestive Heart Failure. Am J Heart 143:398–405.
19. Franzen E, Mangold S, Erz G, Claussen CD, Niess AM, Kramer U, Burgstahler C (2012) Comparison of morphological and functional adaptations of the heart in highly trained triathletes and long-distance runners using cardiac magnetic resonance imaging. Heart Vessels doi:10.1007/s00380-012-0289-7
20. Delnoij T, van Suylen RJ, Cleutjens JP, Schalla S, Bekkers SC (2009) In vivo histology by cardiovascular magnetic resonance imaging, Eur Heart J 30:2492.
21. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, Bauer E, Klövekorn WP, Schlepper M, Schaper W, Schaper J (2000) Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res 86:846–853.
22. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ (2006) Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48:1977–1985.
23. Lehrke S, Lossnitzer D, Schöb M, Steen H, Merten C, Kemmling H, Priebe R, Ehlermann P, Zugck C, Korosoglou G, Gianntisis E, Katus HA (2011) Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 97:727–732.
24. Francis GS, Tang WH (2003) Beta-blockers and reverse remodeling: what are the implications? Am Heart J 145:200–202.
25. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfer EE, Lindenhof J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR (2002) Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357–1365.
26. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G (2011) Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 57:1468–1476.
27. Kawai K, Takaoka H, Hata K, Yokota Y, Yokoyama M (1999) Prevalence, predictors, and prognosis of reversal of maladaptive remodeling with intensive medical therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 84:671–676.
28. Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M (1988) Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic...
nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12:1252–1258

29. Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, Adachi I, Narabayashi I (1997) Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 133:353–358

30. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M (2007) Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J 28:989–995

31. Leong DP, Chakrabarty A, Shipp N, Molaee P, Madsen PL, Joerg L, Sullivan T, Worthley SG, De Pasquale CG, Sanders P, Selvanayagam JB (2012) Effects of myocardial fibrosis and ventricular dysynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J 33:640–648

32. Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, Minamino T, Tsuzimura E, Nagareda T, Kotoh K (1993) Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J Am Coll Cardiol 21:628–633

33. Schalla S, Bekkers SC, Dennert R, van Suylen RJ, Waltenberger J, Crijs HJ, Heymans S (2010) Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy; comparison of magnetic resonance imaging with right ventricular biopsy. Eur J Heart Fail 12:227–231

34. Jellis C, Martin J, Narula J, Marwick TH (2010) Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 56:89–97

35. Messroghli DR, Plein S, Higgins DM, Walters K, Jones TR, Ridgway JP, Sivanathan MU (2006) Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution—reproducibility study. Radiology 238:1004–1012

36. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC (2010) Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122:138–144

37. Croisille P, Revel D, Saeed M (2006) Contrast agents and cardiac MR imaging of myocardial ischemia: from bench to bedside. Eur Radiol 16:1951–1965

38. Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H (2011) Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circ J 75:2605–2613

39. Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, Minamoto T, Tsujimura E, Nagareda T, Kotoh K (1993) Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J Am Coll Cardiol 21:628–633

40. Sinagra G, Rakar S, Zecchin M, Bussani R, Silvestri F, Bassan F, Gregori D, Perkan A, Lenarda A, Secoli G, Lardieri G, Camerini F (1996) Nonpredictive value of fibrosis in dilated cardiomyopathy treated with metoprolol. Cardiovasc Pathol 5:21–28

41. Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA (2011) Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 57:891–903